Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

CRBUCaribou Biosciences, Inc.

Nasdaq · CIK 0001619856
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity typeoperating
SIC2836 Biological Products, (No Diagnostic Substances)
FY end1231
XBRL facts300

Identity from submissions API

NameCaribou Biosciences, Inc.
CIK0001619856
TickersCRBU
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SIC2836 Biological Products, (No Diagnostic Substances)
EIN453728228
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone510-982-6030
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)1

Former names

  • None listed.
Business address
2929 7TH STREET, SUITE 105
BERKELEY
CA
94710
CA
Mailing address
2929 7TH STREET, SUITE 105
BERKELEY
CA
94710
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

326 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-05 10-Q 10-Q 0001619856-26-000061 001-40631 261527307 34 6828373 1 1
2026-11-05 8-K 8-K 2.02,9.01 0001619856-26-000060 001-40631 261527270 34 292532 1 1
2026-10-06 8-K 8-K 2.05,5.02,7.01,8.01,9.01 0001193125-26-415559 001-40631 261444076 34 190346 1 1
2026-08-13 10-Q 10-Q 0001619856-26-000055 001-40631 261273464 34 6649436 1 1
2026-08-13 8-K 8-K 2.02,9.01 0001619856-26-000053 001-40631 261273307 34 315408 1 1
2026-07-27 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-002279 005-92726 261206163 34 10827
2026-06-18 8-K 8-K 5.07,9.01 0001619856-26-000047 001-40631 261102417 34 166236 1 1
2026-06-11 8-K 8-K 7.01,8.01,9.01 0001619856-26-000043 001-40631 261081478 34 381188 1 1
2026-06-05 DEFA14A DEFA14A 0001619856-26-000039 001-40631 261068913 34 290427
2026-05-07 10-Q 10-Q 0001619856-26-000036 001-40631 26953474 34 5944540 1 1
2026-05-07 8-K 8-K 2.02,9.01 0001619856-26-000035 001-40631 26953324 34 295557 1 1
2026-05-01 DEFR14A DEFR14A 0001619856-26-000028 001-40631 26932353 34 2263728 1 1
2026-04-24 ARS ARS 0001619856-26-000024 001-40631 26893495 34 60316623
2026-04-24 DEFA14A DEFA14A 0001619856-26-000023 001-40631 26893461 34 437744
2026-04-24 DEF 14A DEF 14A 0001619856-26-000022 001-40631 26893456 34 2258088 1 1
2026-04-10 PRE 14A PRE 14A 0001619856-26-000015 001-40631 26854767 34 2259803 1 1
2026-03-31 8-K 8-K 7.01,8.01,9.01 0001619856-26-000012 001-40631 26817119 34 249523 1 1
2026-03-05 S-8 S-8 0001193125-26-094237 333-294065 26727334 33 192777 1 1
2026-03-05 10-K 10-K 0001619856-26-000008 001-40631 26726173 34 21794160 1 1
2026-03-05 8-K 8-K 2.02,9.01 0001619856-26-000007 001-40631 26726140 34 338544 1 1
2026-02-27 4 FORM 4 0001754067-26-000004 4540
2026-02-25 144 xsl144X01/primary_doc.xml 0001891113-26-000005 001-40631 26681381 33 4793
2026-02-25 144 xsl144X01/primary_doc.xml 0001231321-26-000007 001-40631 26681380 33 4800
2026-02-25 144 xsl144X01/primary_doc.xml 0001950047-26-001807 001-40631 26680188 33 5361
2026-02-24 4 FORM 4 0001754067-26-000002 9096
2026-02-24 4 FORM 4 0001231321-26-000002 9435
2026-02-24 4 FORM 4 0001891113-26-000002 9459
2026-02-24 4 FORM 4 0001917391-26-000002 9459
2026-02-20 4 FORM 4 0001885914-26-000002 5399
2026-02-20 4 FORM 4 0001880609-26-000002 5407
2026-02-20 4 FORM 4 0001683811-26-000002 5434
2026-02-20 4 FORM 4 0001893193-26-000003 5442
2026-02-20 4 FORM 4 0001733883-26-000004 5468
2026-02-20 4 FORM 4 0001230724-26-000004 5451
2026-02-20 4 FORM 4 0001643875-26-000004 5463
2026-02-20 4 FORM 4 0001762893-26-000002 7284
2026-02-20 4 FORM 4 0001670579-26-000002 8425
2025-11-12 10-Q 10-Q 0001619856-25-000071 001-40631 251472767 34 7236458 1 1
2025-11-12 8-K 8-K 2.02,9.01 0001619856-25-000070 001-40631 251472713 34 320426 1 1
2025-11-03 8-K 8-K 2.02,7.01,8.01,9.01 0001619856-25-000065 001-40631 251442076 34 14404045 1 1
2025-08-12 10-Q 10-Q 0001619856-25-000061 001-40631 251206738 34 7133666 1 1
2025-08-12 8-K 8-K 2.02,9.01 0001619856-25-000060 001-40631 251206697 34 330265 1 1
2025-07-16 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-002538 005-92726 251128476 34 10746
2025-06-23 8-K 8-K 8.01 0001619856-25-000052 001-40631 251062999 34 145446 1 1
2025-06-13 8-K 8-K 5.07,9.01 0001619856-25-000047 001-40631 251046334 34 166157 1 1
2025-05-14 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-001609 333-287093 25948292 33 1744
2025-05-13 CORRESP filename1.htm 0001193125-25-119050 6364
2025-05-12 UPLOAD filename1.pdf 0000000000-25-005015 333-287093 40133
2025-05-08 DEFA14A DEFA14A 0001619856-25-000044 001-40631 25927263 34 296836
2025-05-08 S-3 S-3 0001193125-25-116051 333-287093 25927150 33 1227947
2025-05-08 10-Q 10-Q 0001619856-25-000043 001-40631 25926480 34 6608068 1 1
2025-05-08 8-K 8-K 2.02,9.01 0001619856-25-000040 001-40631 25926006 34 293870 1 1
2025-04-30 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000932471-25-000487 005-92726 25891962 34 6251
2025-04-25 SCHEDULE 13D xslSCHEDULE_13D_X01/primary_doc.xml 0000950170-25-058810 005-92726 25874809 34 188123
2025-04-25 ARS ARS 0001619856-25-000033 001-40631 25873759 34 61377261
2025-04-25 DEFA14A DEFA14A 0001619856-25-000032 001-40631 25873719 34 440923
2025-04-25 DEF 14A DEF 14A 0001619856-25-000031 001-40631 25873667 34 2148988 1 1
2025-04-24 8-K 8-K 2.02,2.05,8.01,9.01 0001619856-25-000023 001-40631 25867565 34 276885 1 1
2025-04-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001576419-25-000713 005-92726 25844666 34 10832
2025-04-11 PRE 14A PRE 14A 0001619856-25-000019 001-40631 25831511 34 1976515 1 1
2025-03-17 4 FORM 4 0001670579-25-000008 6009
2025-03-10 S-8 S-8 0001193125-25-051061 333-285685 25724547 33 77301
2025-03-10 10-K 10-K 0001619856-25-000015 001-40631 25723765 34 13384123 1 1
2025-03-10 8-K 8-K 2.02,9.01 0001619856-25-000014 001-40631 25723730 34 326022 1 1
2025-02-21 4 FORM 4 0001670579-25-000003 8202
2025-02-21 4 FORM 4 0001917391-25-000003 7301
2025-02-21 4 FORM 4 0001231321-25-000003 9961
2025-02-21 4 FORM 4 0001891113-25-000003 9983
2025-02-21 4 FORM 4 0001754067-25-000003 7293
2025-02-21 4 FORM 4 0001871131-25-000003 10172
2025-02-21 4 FORM 4 0001885914-25-000003 5406
2025-02-21 4 FORM 4 0001880609-25-000003 5414
2025-02-21 4 FORM 4 0001683811-25-000003 5441
2025-02-21 4 FORM 4 0001893193-25-000004 5449
2025-02-21 4 FORM 4 0001733883-25-000003 5475
2025-02-21 4 FORM 4 0001230724-25-000003 5458
2025-02-21 4 FORM 4 0001643875-25-000003 5470
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000070858-25-000122 005-92726 25631481 34 27612
2025-01-30 4 FORM 4 0001762893-25-000009 4547
2025-01-13 8-K 8-K 7.01,9.01 0001619856-25-000006 001-40631 25524865 34 277039 1 1
2025-01-10 4 FORM 4 0001762893-25-000006 5569
2025-01-10 3 FORM 3 0001762893-25-000005 335458
2025-01-02 8-K 8-K 5.02,7.01,9.01 0001619856-25-000002 001-40631 25500279 34 754800 1 1
2024-12-06 SC 13D/A SC 13D/A 0001193125-24-272453 005-92726 241532319 34 69168
2024-11-22 4 FORM 4 0001871155-24-000005 4909
2024-11-14 SC 13G/A p24-3175sc13ga.htm 0000902664-24-006658 005-92726 241465318 34 99209
2024-11-14 SC 13G/A d11530039_13g-a.htm 0000919574-24-006775 005-92726 241464898 34 177901
2024-11-14 SC 13G/A SC 13G/A 0001104659-24-118872 005-92726 241461680 34 149461
2024-11-14 SC 13G doc1.htm 0000070858-24-000323 005-92726 241459077 34 91916
2024-11-12 SC 13G/A UnitedStates_13G__CaribouBio.txt 0000932471-24-000855 005-92726 241446487 34 6544
2024-11-06 10-Q 10-Q 0001619856-24-000081 001-40631 241430962 34 8001286 1 1
2024-11-06 8-K 8-K 2.02,9.01 0001619856-24-000080 001-40631 241430937 34 328379 1 1
2024-11-04 SC 13G/A UnitedStates_13G__CaribouBio.txt 0000932471-24-000315 005-92726 241421459 34 5602
2024-10-17 SC 13G/A Caribou_Biosciences_Inc.htm 0000093751-24-000817 005-92726 241376682 34 55853
2024-10-04 3 FORM 3 0001871155-24-000003 343335
2024-09-27 8-K/A 8-K/A 5.02,9.01 0001619856-24-000074 001-40631 241334820 34 159100 1 1
2024-09-03 8-K 8-K 5.02 0001619856-24-000071 001-40631 241273925 34 158866 1 1
2024-08-20 4 FORM 4 0001917391-24-000009 5545
2024-08-20 3 FORM 3 0001917391-24-000008 339655
2024-08-12 8-K 8-K 7.01,8.01,9.01 0001619856-24-000068 001-40631 241194790 34 282828 1 1
2024-08-06 10-Q 10-Q 0001619856-24-000064 001-40631 241179238 34 7189737 1 1
2024-08-06 8-K 8-K 2.02,9.01 0001619856-24-000063 001-40631 241179195 34 330892 1 1
2024-07-16 8-K 8-K 2.02,2.05,9.01 0001619856-24-000054 001-40631 241119683 34 164447 1 1
2024-06-14 8-K 8-K 5.07,9.01 0001619856-24-000050 001-40631 241044639 34 165723 1 1
2024-06-03 8-K 8-K 7.01,8.01,9.01 0001619856-24-000046 001-40631 241011869 34 9849355 1 1
2024-05-07 10-Q 10-Q 0001619856-24-000038 001-40631 24922067 34 6727360 1 1
2024-05-07 8-K 8-K 2.02,9.01 0001619856-24-000036 001-40631 24921952 34 305892 1 1
2024-04-25 ARS ARS 0001619856-24-000028 001-40631 24876254 34 62385894
2024-04-25 DEFA14A DEFA14A 0001619856-24-000027 001-40631 24876153 34 391912
2024-04-25 DEF 14A DEF 14A 0001619856-24-000026 001-40631 24876124 34 1129408
2024-04-04 8-K 8-K 7.01,8.01,9.01 0001619856-24-000018 001-40631 24823163 34 3504862 1 1
2024-03-11 S-8 S-8 0001193125-24-064948 333-277827 24739031 33 78148
2024-03-11 10-K 10-K 0001619856-24-000013 001-40631 24738392 34 19874634 1 1
2024-03-11 8-K 8-K 2.02,9.01 0001619856-24-000012 001-40631 24738333 34 326793 1 1
2024-02-23 SC 13G CARIBOU BIOSCIENCES, INC. 0000902664-24-001995 005-92726 24671373 34 113181
2024-02-22 4 FORM 4 0001628280-24-006433 7506
2024-02-22 4 FORM 4 0001628280-24-006429 7299
2024-02-22 4 FORM 4 0001628280-24-006425 7302
2024-02-22 4 FORM 4 0001628280-24-006421 8202
2024-02-22 4 FORM 4 0001628280-24-006419 7297
2024-02-22 4 FORM 4 0001628280-24-006416 5406
2024-02-22 4 FORM 4 0001628280-24-006414 5414
2024-02-22 4 FORM 4 0001628280-24-006412 5441
2024-02-22 4 FORM 4 0001628280-24-006411 5449
2024-02-22 4 FORM 4 0001628280-24-006407 5475
2024-02-22 4 FORM 4 0001628280-24-006405 5458
2024-02-22 4 FORM 4 0001628280-24-006402 5470
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-023607 005-92726 24637904 34 150093
2024-02-14 SC 13G/A CARIBOU BIOSCIENCES, INC. 0000902664-24-001528 005-92726 24632050 34 116893
2024-02-08 4 FORM 4 0001871131-24-000002 6942
2024-01-25 SC 13G/A us1420381089_012524.txt 0001086364-24-003817 005-92726 24563031 34 13416
2024-01-25 SC 13G/A Caribou_Bio.txt 0000093751-24-000191 005-92726 24558570 34 8395
2024-01-10 3/A FORM 3/A 0001754067-24-000009 300841
2024-01-09 4 FORM 4 0001754067-24-000006 5571
2024-01-09 3 FORM 3 0001754067-24-000004 277062
2024-01-08 SC 13G d10927867_13-g.htm 0000919574-24-000156 005-92726 24520379 34 197187
2024-01-08 8-K 8-K 7.01,8.01,9.01 0001619856-24-000003 001-40631 24518386 34 290724 1 1
2023-12-22 8-K 8-K 5.02,9.01 0001619856-23-000138 001-40631 231509775 34 160517 1 1
2023-12-12 8-K 8-K 5.02,7.01,8.01,9.01 0001619856-23-000134 001-40631 231481242 34 261834 1 1
2023-11-17 10-Q/A 10-Q/A 0001619856-23-000130 001-40631 231418654 34 229798 1 1
2023-11-17 10-Q/A 10-Q/A 0001619856-23-000129 001-40631 231418611 34 229747 1 1
2023-11-07 10-Q 10-Q 0001619856-23-000124 001-40631 231383599 34 7203131 1 1
2023-11-07 8-K 8-K 2.02,9.01 0001619856-23-000123 001-40631 231383569 34 323747 1 1
2023-10-18 8-K 8-K 7.01,8.01,9.01 0001619856-23-000116 001-40631 231330943 34 364581 1 1
2023-09-26 8-K 8-K 1.02,9.01 0001619856-23-000112 001-40631 231280505 34 160174 1 1
2023-08-08 10-Q 10-Q 0001619856-23-000107 001-40631 231151227 34 7183858 1 1
2023-08-08 8-K 8-K 2.02,9.01 0001619856-23-000105 001-40631 231151111 34 326070 1 1
2023-07-20 SC 13G CARIBOU BIOSCIENCES, INC. 0000902664-23-004032 005-92726 231099880 34 131784
2023-07-17 8-K 8-K 1.01,9.01 0001619856-23-000096 001-40631 231090140 34 775777 1 1
2023-07-14 424B5 424B5 0001193125-23-187360 333-266712 231089922 33 634163
2023-07-14 8-K/A 8-K/A 8.01,9.01 0001619856-23-000093 001-40631 231089374 34 2283632 1 1
2023-07-13 424B5 424B5 0001193125-23-186614 333-266712 231087266 33 603297
2023-07-13 8-K 8-K 2.02,7.01,9.01 0001619856-23-000087 001-40631 231087014 34 6847081 1 1
2023-07-13 8-K 8-K 8.01,9.01 0001619856-23-000084 001-40631 231086949 34 2184254 1 1
2023-07-10 SC 13G SC 13G CARIBOU BIOSCIENCES 0000078003-23-000079 005-92726 231078372 34 42768
2023-07-06 8-K 8-K 1.01,3.02,7.01,8.01,9.01 0001619856-23-000079 001-40631 231072125 34 577678 1 1
2023-06-16 8-K 8-K 5.07,9.01 0001619856-23-000076 001-40631 231020958 34 189038 1 1
2023-06-09 4 FORM 4 0001619856-23-000073 7683
2023-05-09 10-Q 10-Q 0001619856-23-000071 001-40631 23901980 34 6882564 1 1
2023-05-09 8-K 8-K 2.02,9.01 0001619856-23-000070 001-40631 23901886 34 320125 1 1
2023-04-28 ARS ARS 0001619856-23-000065 001-40631 23866075 34 60794026
2023-04-28 DEFA14A DEFA14A 0001619856-23-000064 001-40631 23865970 34 373372
2023-04-28 DEF 14A DEF 14A 0001619856-23-000063 001-40631 23865893 34 970806
2023-04-04 8-K 8-K 7.01,8.01,9.01 0001619856-23-000055 001-40631 23795126 34 255117 1 1
2023-03-29 8-K 8-K 7.01,8.01,9.01 0001619856-23-000050 001-40631 23771803 34 258441 1 1
2023-03-29 8-K 8-K 7.01,8.01,9.01 0001619856-23-000049 001-40631 23771801 34 266242 1 1
2023-03-24 8-K 8-K 8.01,9.01 0001619856-23-000042 001-40631 23759879 34 161212 1 1
2023-03-22 4 FORM 4 0001619856-23-000039 7729
2023-03-09 S-8 S-8 0001193125-23-066300 333-270431 23720821 33 76046
2023-03-09 10-K 10-K 0001619856-23-000037 001-40631 23720711 34 21702698 1 1
2023-03-09 8-K 8-K 2.02,9.01 0001619856-23-000035 001-40631 23720661 34 348917 1 1
2023-02-23 4 FORM 4 0001619856-23-000028 5474
2023-02-23 4 FORM 4 0001619856-23-000027 5467
2023-02-23 4 FORM 4 0001619856-23-000026 5421
2023-02-23 4 FORM 4 0001619856-23-000025 5473
2023-02-23 4 FORM 4 0001619856-23-000024 5413
2023-02-23 4 FORM 4 0001619856-23-000023 5442
2023-02-23 4 FORM 4 0001619856-23-000022 5430
2023-02-23 4 FORM 4 0001619856-23-000021 5469
2023-02-23 4 FORM 4 0001619856-23-000020 5482
2023-02-23 4 FORM 4 0001619856-23-000019 5378
2023-02-23 4 FORM 4 0001619856-23-000018 5386
2023-02-23 4 FORM 4 0001619856-23-000017 5465
2023-02-23 4 FORM 4 0001619856-23-000016 5447
2023-02-14 SC 13G/A SC 13G/A 0001104659-23-021580 005-92726 23628970 34 122221
2023-02-09 SC 13G/A filing.txt 0000315066-23-001350 005-92726 23601206 34 7920
2023-02-03 SC 13G Caribou_Biosciences_Inc.txt 0000093751-23-000161 005-92726 23585260 34 8406
2023-02-03 SC 13G us1420381089_020323.txt 0001306550-23-007127 005-92726 23584766 34 13218
2023-01-20 4 FORM 4 0001619856-23-000002 4795
2022-12-16 8-K 8-K 5.02,9.01 0001619856-22-000039 001-40631 221467958 34 181234 1 1
2022-12-12 8-K 8-K 7.01,8.01,9.01 0001619856-22-000036 001-40631 221456180 34 470163 1 1
2022-12-02 4 FORM 4 0001619856-22-000031 6875
2022-11-29 8-K 8-K 7.01,8.01,9.01 0001619856-22-000029 001-40631 221428634 34 277166 1 1
2022-11-21 8-K 8-K 7.01,8.01,9.01 0001619856-22-000025 001-40631 221403642 34 605440 1 1
2022-11-08 10-Q 10-Q 0001619856-22-000022 001-40631 221369256 34 8902424 1 1
2022-11-08 8-K 8-K 2.02,9.01 0001619856-22-000019 001-40631 221368837 34 339594 1 1
2022-11-03 8-K 8-K 7.01,9.01 0001619856-22-000010 001-40631 221356448 34 274010 1 1
2022-10-18 8-K 8-K 7.01,9.01 0001619856-22-000007 001-40631 221315014 34 278938 1 1
2022-10-07 4 FORM 4 0001619856-22-000003 13073
2022-09-23 8-K/A 8-K/A 5.07,9.01 0000950170-22-018793 001-40631 221260311 34 209190 1 1
2022-09-22 8-K 8-K 5.07,9.01 0000950170-22-018768 001-40631 221259289 34 201942 1 1
2022-09-16 4 FORM 4 SUBMISSION 0001209191-22-050315 10897
2022-08-26 4 FORM 4 SUBMISSION 0001209191-22-047748 9457
2022-08-24 4 FORM 4 SUBMISSION 0001209191-22-047370 5482
2022-08-24 4 FORM 4 SUBMISSION 0001209191-22-047368 4960
2022-08-16 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2022-08-16 16:00:00 9999999995-22-002403 333-266712 221171943 33 1703
2022-08-12 CORRESP filename1.htm 0001193125-22-219961 6092
2022-08-12 8-K 8-K 1.01,9.01 0000950170-22-017117 001-40631 221159905 34 184567 1 1
2022-08-11 UPLOAD filename1.pdf 0000000000-22-008557 40240
2022-08-11 DEFA14A DEFA14A 0000950170-22-016867 001-40631 221155801 34 1469072
2022-08-11 DEFA14A DEFA14A 0000950170-22-016855 001-40631 221155699 34 69742
2022-08-11 DEF 14A DEF 14A 0000950170-22-016847 001-40631 221155621 34 1304578
2022-08-09 S-3 S-3 0001193125-22-216271 333-266712 221149157 33 1420568
2022-08-09 10-Q 10-Q 0000950170-22-016053 001-40631 221148409 34 13479103 1 1
2022-08-09 8-K 8-K 2.02,8.01,9.01 0000950170-22-016031 001-40631 221148180 34 577883 1 1
2022-07-18 8-K/A 8-K/A 5.02 0000950170-22-012759 001-40631 221089229 34 168649 1 1
2022-07-15 8-K 8-K 8.01 0000950170-22-012732 001-40631 221086370 34 161855 1 1
2022-06-10 8-K 8-K 7.01,8.01,9.01 0000950170-22-011433 001-40631 221007653 34 3731964 1 1
2022-06-01 SC 13G/A SC 13G/A 0001193125-22-165343 005-92726 22988383 34 37578
2022-06-01 8-K 8-K 7.01,9.01 0000950170-22-011024 001-40631 22987489 34 234787 1 1
2022-05-18 4 FORM 4 SUBMISSION 0001209191-22-030288 5284
2022-05-17 4 FORM 4 SUBMISSION 0001209191-22-029893 11571
2022-05-12 3 FORM 3 SUBMISSION 0001209191-22-028617 6299
2022-05-12 8-K 8-K 7.01,8.01,9.01 0000950170-22-009499 001-40631 22916182 34 2424698 1 1
2022-05-11 8-K 8-K 5.02,7.01,9.01 0000950170-22-009315 001-40631 22913741 34 278628 1 1
2022-05-10 4 FORM 4 SUBMISSION 0001209191-22-028170 8391
2022-05-10 4/A FORM 4/A SUBMISSION 0001209191-22-028169 8988
2022-05-09 10-Q 10-Q 0000950170-22-008513 001-40631 22905390 34 12015742 1 1
2022-05-09 8-K 8-K 2.02,9.01 0000950170-22-008491 001-40631 22905041 34 427178 1 1
2022-05-06 4 FORM 4 SUBMISSION 0001209191-22-027696 11753
2022-04-25 8-K 8-K 7.01 0000950170-22-006094 001-40631 22849917 34 272454 1 1
2022-03-21 S-8 S-8 CRBU 2022 0001564590-22-011219 333-263750 22756358 33 177499
2022-03-21 10-K 10-K 0000950170-22-004233 001-40631 22755924 34 34762234 1 1
2022-03-21 8-K 8-K 2.02,9.01 0000950170-22-004230 001-40631 22755832 34 491642 1 1
2022-03-17 4 FORM 4 SUBMISSION 0001209191-22-019808 11963
2022-03-07 4 FORM 4 SUBMISSION 0001209191-22-016872 11770
2022-03-01 SC 13G SC 13G 0001193125-22-061426 005-92726 22698969 34 39803
2022-02-14 SC 13G/A SC 13G/A 0001104659-22-022219 005-92726 22628172 34 140575
2022-02-11 SC 13G/A AMENDMENT #1 0000908834-22-000085 005-92726 22618863 34 390552
2022-02-09 5 FORM 5 SUBMISSION 0001209191-22-008027 6824
2022-02-08 4 FORM 4 SUBMISSION 0001209191-22-007860 7186
2022-02-04 SC 13D SC 13D 0000950170-22-000764 005-92726 22591147 34 159632
2022-01-27 4 FORM 4 SUBMISSION 0001209191-22-005222 7461
2022-01-25 4 FORM 4 SUBMISSION 0001209191-22-004860 7545
2022-01-24 3 FORM 3 SUBMISSION 0001209191-22-004600 7451
2022-01-19 8-K 8-K 1.01,2.03,9.01 0000950170-22-000401 001-40631 22539009 34 1589905 1 1
2022-01-18 8-K 8-K 8.01,9.01 0000950170-22-000354 001-40631 22533668 34 276061 1 1
2022-01-12 4 FORM 4 SUBMISSION 0001209191-22-003062 11562
2021-12-22 4/A FORM 4/A SUBMISSION 0001209191-21-071011 5930
2021-12-21 4 FORM 4 SUBMISSION 0001209191-21-070829 5407
2021-12-21 4 FORM 4 SUBMISSION 0001209191-21-070825 5416
2021-12-21 4 FORM 4 SUBMISSION 0001209191-21-070823 5442
2021-12-21 4 FORM 4 SUBMISSION 0001209191-21-070819 5537
2021-12-21 4 FORM 4 SUBMISSION 0001209191-21-070814 5541
2021-12-21 4 FORM 4 SUBMISSION 0001209191-21-070810 5539
2021-12-21 4 FORM 4 SUBMISSION 0001209191-21-070804 5546
2021-12-21 4 FORM 4 SUBMISSION 0001209191-21-070799 5412
2021-12-21 4 FORM 4 SUBMISSION 0001209191-21-070797 10011
2021-12-21 4 FORM 4 SUBMISSION 0001209191-21-070795 5472
2021-12-08 4 FORM 4 SUBMISSION 0001209191-21-068582 11559
2021-11-16 4 FORM 4 SUBMISSION 0001209191-21-064866 5581
2021-11-15 4 FORM 4 SUBMISSION 0001209191-21-064491 5265
2021-11-10 3 FORM 3 SUBMISSION 0001209191-21-063906 6238
2021-11-09 10-Q 10-Q 0000950170-21-003759 001-40631 211392536 34 11776975 1 1
2021-11-09 8-K 8-K 2.02,9.01 0000950170-21-003749 001-40631 211392271 34 465958 1 1
2021-11-08 3 FORM 3 SUBMISSION 0001209191-21-063404 6341
2021-11-08 8-K 8-K 5.02,7.01,9.01 0000950170-21-003322 001-40631 211386733 34 207932 1 1
2021-10-21 4 FORM 4 SUBMISSION 0001209191-21-061294 11814
2021-10-13 4 FORM 4 SUBMISSION 0001209191-21-060424 15121
2021-10-12 4 FORM 4 SUBMISSION 0001209191-21-060289 7475
2021-10-04 4 FORM 4 SUBMISSION 0001209191-21-058926 5187
2021-10-01 3 FORM 3 SUBMISSION 0001209191-21-058562 6436
2021-09-29 8-K 8-K 5.02,7.01,9.01 0000950170-21-001925 001-40631 211291852 34 276711 1 1
2021-09-09 4 FORM 4 SUBMISSION 0001209191-21-055280 8539
2021-09-02 10-Q 10-Q 0000950170-21-001660 001-40631 211233591 34 11812998 1 1
2021-09-02 8-K 8-K 2.02,9.01 0000950170-21-001658 001-40631 211233458 34 450446 1 1
2021-08-31 3 FORM 3 SUBMISSION 0001209191-21-054086 6337
2021-08-25 8-K 8-K 5.02,7.01,9.01 0000950170-21-001559 001-40631 211207021 34 265323 1 1
2021-08-06 SC 13G SC 13G 0001104659-21-101539 005-92726 211153704 34 138968
2021-08-03 SC 13G SC 13G 0001104659-21-099583 005-92726 211141223 34 443236
2021-07-29 SC 13G filing.txt 0000315066-21-001646 005-92726 211126774 34 7524
2021-07-29 4 PRIMARY DOCUMENT 0000315066-21-001645 20846
2021-07-28 8-K 8-K 3.02,5.02,5.03,8.01,9.01 0001193125-21-227378 001-40631 211122580 34 422186
2021-07-26 S-8 S-8 0001193125-21-224325 333-258173 211114310 33 527415
2021-07-23 424B4 424B4 0001193125-21-223038 333-257604 211111110 33 5653687
2021-07-23 3 FORM 3 SUBMISSION 0000899243-21-029606 9998
2021-07-22 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2021-07-22 16:00:00 9999999995-21-002886 333-257604 211108953 33 1703
2021-07-22 S-1MEF S-1MEF 0001193125-21-222147 333-258105 211108928 33 60007
2021-07-22 3 FORM 3 SUBMISSION 0000899243-21-029587 11320
2021-07-22 3 FORM 3 SUBMISSION 0000899243-21-029586 7873
2021-07-22 3 FORM 3 SUBMISSION 0000899243-21-029585 12205
2021-07-22 3 FORM 3 SUBMISSION 0000899243-21-029582 9610
2021-07-22 3 FORM 3 SUBMISSION 0000899243-21-029580 7930
2021-07-22 3 FORM 3 SUBMISSION 0000899243-21-029579 2908
2021-07-22 3 FORM 3 SUBMISSION 0000899243-21-029578 9989
2021-07-22 3 FORM 3 SUBMISSION 0000899243-21-029576 10125
2021-07-22 3 PRIMARY DOCUMENT 0000315066-21-001642 9952
2021-07-22 SEC STAFF LETTER filename1.pdf 9999999997-21-004268 271755
2021-07-22 FWP FWP 0001193125-21-221335 333-257604 211105969 34 132276
2021-07-22 S-1/A S-1/A 0001193125-21-221318 333-257604 211105919 33 5784413
2021-07-21 CERT 8ACERT_CRBU.pdf 0001354457-21-000825 001-40631 211104333 34 996256
2021-07-20 CORRESP filename1.htm 0001193125-21-219033 12432
2021-07-20 CORRESP filename1.htm 0001193125-21-218918 6934
2021-07-19 8-A12B 8-A12B 0001193125-21-218592 001-40631 211097970 34 14144
2021-07-19 S-1/A S-1/A 0001193125-21-217974 333-257604 211096778 33 6736170
2021-07-12 CORRESP filename1.htm 0001193125-21-212757 92783
2021-07-01 CORRESP filename1.htm 0001193125-21-206273 33722
2021-07-01 S-1 S-1 0001193125-21-206262 333-257604 211065853 33 10111047
2021-06-23 UPLOAD filename1.pdf 0000000000-21-007723 46912
2021-06-11 DRSLTR filename1.htm 0000950123-21-007772 66272
2021-06-11 DRS/A filename1.htm 0000950123-21-007771 377-04806 211011144 33 6783170
2021-06-02 UPLOAD filename1.pdf 0000000000-21-006847 61832
2021-05-18 SEC STAFF LETTER filename1.pdf 9999999997-21-002899 272615
2021-05-07 DRS filename1.htm 0000950123-21-005591 377-04806 21903519 33 9096325
2021-03-05 D xslFormDX01/primary_doc.xml 06b 0001619856-21-000002 021-391380 21717905 33 12425
2019-03-25 SC 13G/A AMENDMENT NO. 3 0001654954-19-003213 90507
2019-01-16 SC 13G/A AMENDMENT NO. 2 0001654954-19-000534 85846
2018-02-06 SC 13G/A PRIMARY DOCUMENT 0001654954-18-001121 86519
2018-01-30 4 xslF345X03/form4-01302018_020115.xml 0001415889-18-000152 001-37766 18560212 34 5954
2017-09-13 4 xslF345X03/form4-09132017_030948.xml 0001415889-17-001484 001-37766 171084091 34 5565
2017-02-28 SC 13G SCHEDULE 13G 0001654954-17-001508 86352
2016-05-25 D xslFormDX01/primary_doc.xml 06b 0001619856-16-000005 021-263801 161673287 33 11343
2016-05-11 4 FORM 4 SUBMISSION 0001209191-16-119294 001-37766 161641203 34 13282
2016-05-05 3 FORM 3 SUBMISSION 0001209191-16-117931 001-37766 161625417 34 17398
2015-03-24 D/A xslFormDX01/primary_doc.xml 06b 0001619856-15-000001 021-225136 15721793 33 9099
2014-09-23 D xslFormDX01/primary_doc.xml 06b 0001619856-14-000001 021-225136 141114969 33 7405

Latest XBRL company facts

One latest value per concept from companyfacts (300 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 108.04M 2026-11-02 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
dei EntityPublicFloat Entity Public Float USD 112.50M 2025-06-30 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 5.05M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AccountsPayableRelatedPartiesCurrent Accounts Payable, Related Parties, Current USD 0 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004233
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 518,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 535,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AccruedIncomeTaxesCurrent Accrued Income Taxes, Current USD 5,000 2021-06-30 2021 Q2 10-Q 2021-09-02 0000950170-21-001660
us-gaap AccruedLiabilitiesAndOtherLiabilities Accrued Liabilities and Other Liabilities USD 13.27M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 13.27M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AccruedLiabilitiesCurrentAndNoncurrent Accrued Liabilities USD 400,000 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 407,000 2021-09-30 2021 Q3 10-Q 2021-11-09 0000950170-21-003759
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 13.53M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1 Accumulated Depreciation, Depletion and Amortization, Reclassifications from Property, Plant and Equipment USD 1.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -80,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 749.20M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 2.16M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 1.20M 2021-06-01 2021-06-30 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 7.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AllowanceForDoubtfulOtherReceivablesCurrent Allowance for Doubtful Other Receivables, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 17.35M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AreaOfRealEstateProperty Area of Real Estate Property sqft 10,000 2022-01-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap AssetImpairmentCharges Asset Impairment Charges USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap Assets Assets USD 123.03M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AssetsCurrent Assets, Current USD 100.08M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 81,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 318.56M 2022-12-31 2023 Q1 10-Q 2023-05-09 0001619856-23-000071
us-gaap AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost USD 126.98M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost USD 3.50M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost USD 130.49M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 317.04M 2022-12-31 2023 Q1 10-Q 2023-05-09 0001619856-23-000071
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 68.74M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Debt Securities, Available-for-sale, Noncurrent USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 0 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001619856-26-000055
us-gaap CapitalizedContractCostNetCurrent Capitalized Contract Cost, Net, Current USD 2.09M 2022-06-30 2022 Q2 10-Q 2022-08-09 0000950170-22-016053
us-gaap CapitalLeaseObligations Capital Lease Obligations USD 100,000 2020-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004233
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 26.06M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 94.80M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 26.06M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 112.15M 2022-06-30 2022 Q2 10-Q 2022-08-09 0000950170-22-016053
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 13.65M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap CommodityContractAssetCurrent Commodity Contract Asset, Current USD 0 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004233
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 30.68M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 300.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 108.04M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 108.04M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap CommonStockValue Common Stock, Value, Issued USD 11,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -76.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ContractWithCustomerAssetNetCurrent Contract with Customer, Asset, after Allowance for Credit Loss, Current USD 623,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ContractWithCustomerLiability Contract with Customer, Liability USD 1.74M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 370,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 1.37M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized USD 1.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ConversionOfStockAmountIssued1 Conversion of Stock, Amount Issued USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 1,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 1,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DebtInstrumentFaceAmount Debt Instrument, Face Amount USD 1.10M 2018-11-30 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage pure 0.03 2018-11-30 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD -385,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredFinanceCostsNet Debt Issuance Costs, Net USD 0 2022-12-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD -551,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 4.26M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredIncomeTaxLiabilitiesNet Deferred Income Tax Liabilities, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 0 2022-12-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap DeferredRevenue Deferred Revenue USD 12.64M 2022-06-30 2022 Q2 10-Q 2022-08-09 0000950170-22-016053
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 0 2022-06-30 2022 Q2 10-Q 2022-08-09 0000950170-22-016053
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 15.63M 2022-06-30 2022 Q2 10-Q 2022-08-09 0000950170-22-016053
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD -166,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredTaxAssetsEquityMethodInvestments Deferred Tax Assets, Equity Method Investments USD 37,000 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 191.19M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 30.56M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 4.26M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredTaxAssetsStateTaxes Deferred Tax Assets, State Taxes USD 7,000 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 6.64M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredTaxAssetsTaxDeferredExpenseOther Deferred Tax Assets, Tax Deferred Expense, Other USD 801,000 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities USD 1.68M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 186.92M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 548,000 2024-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates Deferred Tax Liabilities, Investment in Noncontrolled Affiliates USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredTaxLiabilitiesLeasingArrangements Deferred Tax Liabilities, Leasing Arrangements USD 4.26M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 1.86M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap Dividends Dividends USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap DividendsPayableCurrentAndNoncurrent Dividends Payable USD 0 2021-06-30 2021 Q2 10-Q 2021-09-02 0000950170-21-001660
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.75 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.32 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008513
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.75 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0.004 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.233 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure 0.01 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.015 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent pure 0.01 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.005 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Percent pure -0.014 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.051 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 6.37M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 10.40M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap EquityMethodInvestments Equity Method Investments USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap EquitySecuritiesFvNiGainLoss Equity Securities, FV-NI, Gain (Loss) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ExtinguishmentOfDebtAmount Extinguishment of Debt, Amount USD 0 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-08 0001619856-22-000022
us-gaap ExtinguishmentOfDebtGainLossNetOfTax Extinguishment of Debt, Gain (Loss), Net of Tax USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap FinanceLeaseLiability Finance Lease, Liability USD 0 2022-09-30 2022 Q3 10-Q 2022-11-08 0001619856-22-000022
us-gaap FinanceLeasePrincipalPayments Finance Lease, Principal Payments USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap GainLossOnDispositionOfAssets1 Gain (Loss) on Disposition of Assets USD 254,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 23.86M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ImpairmentOfLeasehold Impairment of Leasehold USD 10.00M 2025-04-01 2025-06-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -148.70M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -148.68M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap IncomeTaxesPaid Income Taxes Paid USD 170,000 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-07 0001619856-23-000124
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-10 0001619856-25-000015
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-07 0001619856-26-000036
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 34.62M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -31.22M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 2.23M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD -693,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap IncomeTaxReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Amount USD 2.03M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 7.57M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -677,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 449,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD -3.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap IncreaseDecreaseInContractWithCustomerAsset Increase (Decrease) in Contract with Customer, Asset USD -383,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD -1.91M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap IncreaseDecreaseInDeferredLiabilities Increase (Decrease) in Deferred Liabilities USD -548,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD -2.47M 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-09 0000950170-22-016053
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -889,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD -775,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap IncreaseDecreaseInOtherOperatingLiabilities Increase (Decrease) in Other Operating Liabilities USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-11 0001619856-24-000013
us-gaap IncreaseDecreaseInOtherReceivables Increase (Decrease) in Other Receivables USD -1.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 573,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap InterestExpense Interest Expense USD 0 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008513
us-gaap InterestIncomeOther Interest Income, Other USD 148,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004233
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 0 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008513
us-gaap LeaseCost Lease, Cost USD 7.91M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 43.81M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 13.77M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 4.84M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 6.95M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 6.73M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 6.51M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 5.01M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 797,000 2024-09-30 2024 Q3 10-Q 2024-11-06 0001619856-24-000081
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 16.59M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap Liabilities Liabilities USD 46.39M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 123.03M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap LiabilitiesCurrent Liabilities, Current USD 20.14M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap LinesOfCreditCurrent Line of Credit, Current USD 18,000 2024-12-31 2024 FY 10-K 2025-03-10 0001619856-25-000015
us-gaap LitigationReserve Estimated Litigation Liability USD 3.90M 2024-09-30 2024 Q3 10-Q 2024-11-06 0001619856-24-000081
us-gaap LitigationSettlementAmountAwardedToOtherParty Litigation Settlement, Amount Awarded to Other Party USD 3.90M 2024-01-01 2024-03-31 2024 Q3 10-Q 2024-11-06 0001619856-24-000081
us-gaap LongTermInvestments Long-term Investments USD 0 2020-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004233
us-gaap LongTermLoansPayable Loans Payable, Noncurrent USD 0 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004233
us-gaap MarketableSecurities Marketable Securities USD 930,000 2024-12-31 2024 FY 10-K 2025-03-10 0001619856-25-000015
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 227.78M 2022-06-30 2022 Q2 10-Q 2022-08-09 0000950170-22-016053
us-gaap MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap MarketableSecuritiesNoncurrent Marketable Securities, Noncurrent USD 26.15M 2022-06-30 2022 Q2 10-Q 2022-08-09 0000950170-22-016053
us-gaap MarketableSecuritiesUnrealizedGainLoss Marketable Securities, Unrealized Gain (Loss) USD -492,000 2022-04-01 2022-06-30 2022 Q2 10-Q 2022-08-09 0000950170-22-016053
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 23.62M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 62.32M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -72.29M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -75.98M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 3.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap NotesAndLoansPayable Notes and Loans Payable USD 0 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004233
us-gaap NumberOfOperatingSegments Number of Operating Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap NumberOfReportableSegments Number of Reportable Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap OperatingExpenses Operating Expenses USD 84.76M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -79.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap OperatingLeaseCost Operating Lease, Cost USD 7.63M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 1.80M 2022-01-01 2022-01-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 27.23M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 1.46M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 24.88M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap OperatingLeasePayments Operating Lease, Payments USD 4.31M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 16.71M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals USD 0 2021-12-31 2022 Q3 10-Q 2022-11-08 0001619856-22-000022
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.138 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 1.00M 2021-06-30 2021 Q2 10-Q 2021-09-02 0000950170-21-001660
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 1.38M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Noncontrolling Interest USD -492,000 2022-04-01 2022-06-30 2022 Q2 10-Q 2022-08-09 0000950170-22-016053
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -1.38M 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD -9,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -183,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap OtherIncome Other Income USD 8.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap OtherLiabilities Other Liabilities USD 0 2022-12-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap OtherLiabilitiesCurrent Other Liabilities, Current USD 2.03M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap OtherNonoperatingIncome Other Nonoperating Income USD 3.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap OtherPrepaidExpenseCurrent Other Prepaid Expense, Current USD 3.39M 2025-09-30 2025 Q3 10-Q 2025-11-12 0001619856-25-000071
us-gaap OtherReceivables Other Receivables USD 1.45M 2026-03-31 2026 Q1 10-Q 2026-05-07 0001619856-26-000036
us-gaap OtherReceivablesNetCurrent Other Receivables, Net, Current USD 647,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap PaymentsForLegalSettlements Payments for Legal Settlements USD 3.90M 2024-04-22 2025 Q1 10-Q 2025-05-08 0001619856-25-000043
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 28.60M 2021-07-01 2021-09-30 2022 Q3 10-Q 2022-11-08 0001619856-22-000022
us-gaap PaymentsToAcquireInProcessResearchAndDevelopment Payments to Acquire in Process Research and Development USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap PaymentsToAcquireIntangibleAssets Payments to Acquire Intangible Assets USD 300,000 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-08 0001619856-22-000022
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 58.53M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 92,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap PreferredStockLiquidationPreferenceValue Preferred Stock, Liquidation Preference, Value USD 41.62M 2020-12-31 2021 Q3 10-Q 2021-11-09 0000950170-21-003759
us-gaap PreferredStockNoParValue Preferred Stock, No Par Value USD/shares 0 2022-06-30 2022 Q2 10-Q 2022-08-09 0000950170-22-016053
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2023-09-30 2023 Q3 10-Q 2023-11-07 0001619856-23-000124
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2023-09-30 2023 Q3 10-Q 2023-11-07 0001619856-23-000124
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2023-09-30 2023 Q3 10-Q 2023-11-07 0001619856-23-000124
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2023-09-30 2023 Q3 10-Q 2023-11-07 0001619856-23-000124
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2023-09-30 2023 Q3 10-Q 2023-11-07 0001619856-23-000124
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 3.49M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap PrepaidInsurance Prepaid Insurance USD 540,000 2025-03-31 2025 Q1 10-Q 2025-05-08 0001619856-25-000043
us-gaap PrepaidRent Prepaid Rent USD 0 2022-12-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap PrepaidTaxes Prepaid Taxes USD 0 2023-12-31 2023 FY 10-K 2024-03-11 0001619856-24-000013
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 22.82M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-10 0001619856-25-000015
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised USD 770,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale USD 252.87M 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap ProceedsFromOtherDebt Proceeds from Other Debt USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004233
us-gaap ProceedsFromRepaymentsOfNotesPayable Proceeds from (Repayments of) Notes Payable USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale USD 120.62M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ProceedsFromSaleOfAvailableForSaleSecuritiesEquity Proceeds from Sale of Available-for-sale Securities, Equity USD 7.67M 2020-01-01 2020-09-30 2021 Q3 10-Q 2021-11-09 0000950170-21-003759
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 317,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 619,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-06 0001619856-24-000081
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -75.98M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 18.40M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 4.87M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap RepaymentsOfLongTermCapitalLeaseObligations Repayments of Long-term Capital Lease Obligations USD 0 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-09 0000950170-22-016053
us-gaap RepaymentsOfSecuredDebt Repayments of Secured Debt USD 1.15M 2021-04-01 2021-06-30 2022 Q3 10-Q 2022-11-08 0001619856-22-000022
us-gaap ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff Research and Development Asset Acquired Other than Through Business Combination, Written-off USD 1.63M 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-06 0001619856-24-000081
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 60.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost Research and Development Expense, Software (Excluding Acquired in Process Cost) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap ResearchAndDevelopmentInProcess Research and Development in Process USD 0 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-08 0001619856-22-000022
us-gaap RestrictedCash Restricted Cash USD 100,000 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap RestrictedCashAndCashEquivalentsAtCarryingValue Restricted Cash and Cash Equivalents, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminated Restructuring and Related Cost, Number of Positions Eliminated employee 47 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent pure 0.32 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap RestructuringCharges Restructuring Charges USD 600,000 2024-07-01 2024-09-30 2024 FY 10-K 2025-03-10 0001619856-25-000015
us-gaap RestructuringCostsAndAssetImpairmentCharges Restructuring Costs and Asset Impairment Charges USD 14.43M 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -672.49M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 5.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap RevenueFromRelatedParties Revenue from Related Parties USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004233
us-gaap RevenueNotFromContractWithCustomer Revenue Not from Contract with Customer USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004233
us-gaap RevenueRemainingPerformanceObligation Revenue, Remaining Performance Obligation, Amount USD 1.70M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap Revenues Revenues USD 0 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-09-02 0000950170-21-001660
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 2.09M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap SaleOfStockConsiderationReceivedOnTransaction Sale of Stock, Consideration Received on Transaction USD 50.00M 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-09-02 0000950170-21-001660
us-gaap SecurityDeposit Security Deposit USD 400,000 2022-01-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap SeveranceCosts1 Severance Costs USD 1.84M 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 7.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period shares 1.14M 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-06 0001619856-24-000064
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 6.33 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-06 0001619856-24-000064
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period shares 78,596 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-07 0001619856-23-000124
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value USD/shares 10.04 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-07 0001619856-23-000124
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.758 2024-07-01 2024-09-30 2024 Q3 10-Q 2024-11-06 0001619856-24-000081
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.899 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.861 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.045 2024-04-01 2024-06-30 2024 Q2 10-Q 2024-08-06 0001619856-24-000064
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.046 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.038 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant shares 6.84M 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008513
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 1,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 9.54M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 6.18 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 1.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 2.68 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 3.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 2,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 14.71M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 4.86 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 2,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 14.71M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 4.86 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value USD/shares 2.99 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-09-02 0000950170-21-001660
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent pure 0.85 2021-07-01 2021-07-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 1.36 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 1.8 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap SharesOutstanding Shares, Outstanding shares 8.89M 2020-06-30 2021 Q2 10-Q 2021-09-02 0000950170-21-001660
us-gaap ShortTermInvestments Short-term Investments USD 0 2020-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004233
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 277,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 76.63M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 1.818 2021-07-01 2021-07-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures shares 15,000 2024-01-01 2024-03-31 2024 Q2 10-Q 2024-08-06 0001619856-24-000064
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 22,206 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 150.15M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-09 0001619856-23-000037
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 302,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 2.68M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap StockIssuedDuringPeriodValueOther Stock Issued During Period, Value, Other USD 2.14M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004233
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 10,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 41.32M 2020-12-31 2021 Q3 10-Q 2021-11-09 0000950170-21-003759
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 10.03M 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions USD 339,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 2.06M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 305,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-11 0001619856-24-000013
us-gaap UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate USD 0 2024-12-31 2024 FY 10-K 2025-03-10 0001619856-25-000015
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 39.61M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap VariableLeaseCost Variable Lease, Cost USD 2.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001619856-26-000008
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 101.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 60.55M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008513
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 101.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001619856-26-000061

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →